I've spent my career at the intersection of HEOR, market access, and rare disease — at Vertex, Novo Nordisk, and now Jazz Pharmaceuticals, where I lead global value strategy across neuroscience and neuro-oncology.

I've led U.S. HEOR strategy through multiple rare disease launches. I've led global evidence planning and payer pull-through. I've supported BD&L buy-side diligence on payer value and pricing. I've built an HEOR team from the ground up. I've run early assets for market access as early as pre-IND. I've figured out where HEOR can succeed — and when it cannot.

I know what it costs to figure this out the hard way.

I've served on the ISPOR New Professionals Steering Committee. I've given guest lectures at universities I didn't attend, spoken on panels I wasn't paid for, and stayed an hour past every conference session because someone in the hallway had a question they couldn't ask anywhere else.

That last part matters. I've been doing it for years — informally, inconsistently, and always wishing there was a better structure for it.